Coave Therapeutics

Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT

Paris, France, 4th May 2022 – Coave Therapeutics (ëCoaveí), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announced that research on its AAV-Ligand Conjugates platform (ALIGATER) will be presented at the 2022 American Society of Cell & Gene Therapy (ASCGT) meeting, which will be…
63bis avenue Ledru Rolin 75012 Paris